Evidence map›Paper›PMID 36827451›Full record

ArticlePLoS pathogens2023

BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.

Janmejay Singh, Anbalagan Anantharaj, Aleksha Panwar, Chitra Rani, Monika Bhardwaj, Parveen Kumar, Partha Chattopadhyay, Priti Devi, Ranjeet Maurya, Pallavi Mishra and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Janmejay SinghBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Anbalagan AnantharajBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Aleksha PanwarBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Chitra RaniBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Monika BhardwajBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Parveen KumarBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Partha ChattopadhyayINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Priti DeviINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Ranjeet MauryaINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Pallavi MishraINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Anil Kumar PandeyEmployees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
Rajesh PandeyINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Guruprasad R MedigeshiBioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.ORCID 0000-0001-5333-9743
Translational Health Science and Technology Institute · INInstitute of Genomics and Integrative Biology · INEmployees' State Insurance Model Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and previously-infected individuals due to its ability to evade neutralization by antibodies. With multiple sub-lineages of Omicron emerging in the last 12 months, there is inadequate information on the quantitative antibody response generated upon natural infection with Omicron variant and whether these antibodies offer cross-protection against other sub-lineages of Omicron variant. In this study, we characterized the growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells. Relatively higher amounts infectious virus titers, cytopathic effect and disruption of epithelial barrier functions was observed with Delta variant whereas infection with Omicron sub-lineages led to a more robust induction of interferon pathway, lower level of virus replication and mild effect on epithelial barrier. The replication kinetics of BA.1, BA.2 and BA.2.75 sub-lineages of the Omicron variant were comparable in cell culture and natural infection in a subset of individuals led to a significant increase in binding and neutralizing antibodies to the Delta variant and all the three sub-lineages of Omicron but the level of neutralizing antibodies were lowest against the BA.2.75 variant. Finally, we show that Cu2+, Zn2+ and Fe2+ salts inhibited in vitro RdRp activity but only Cu2+ and Fe2+ inhibited both the Delta and Omicron variants in cell culture. Thus, our results suggest that high levels of interferons induced upon infection with Omicron variant may counter virus replication and spread. Waning neutralizing antibody titers rendered subjects susceptible to infection by Omicron variants and natural Omicron infection elicits neutralizing antibodies that can cross-react with other sub-lineages of Omicron and other variants of concern.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesHumansInterferonsKineticsSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesInterferons

Identifiers

PMID36827451
PMCPMC9994724
OpenAlexW4321765768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.